Clinical Trials Directory

Trials / Completed

CompletedNCT04157985

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
161 (actual)
Sponsor
Dan Zandberg · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.

Detailed description

Within the UPMC system, approximately 2,300 patients received PD-1/PD-L1 therapy for a variety of advanced solid tumors within the past year. It is anticipated that this number will increase as the clinical indications for treatment with these agents also increase. The investigators conducted a survey of 60 Medical Oncologists within the UPMC system regarding their interest in a trial that will attempt to address the question of optimal length of PD-1/PD-L1 treatment. Fifty-two (86.7%) physicians indicated that they would participate in a clinical trial that had a primary goal of determining whether it was feasible to stop immunotherapy after 1 year of treatment.

Conditions

Interventions

TypeNameDescription
DRUGContinue PD-1/PD-L1 Inhibitors treatmentContinued treatment with PD-1/PD-L1-1 inhibitor
OTHERDiscontinue PD-1/PD-L1-1 inhibitorDiscontinued treatment with PD-1/PD-L1-1 inhibitor

Timeline

Start date
2019-11-15
Primary completion
2025-10-14
Completion
2025-11-07
First posted
2019-11-08
Last updated
2025-12-11

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04157985. Inclusion in this directory is not an endorsement.